ABUS - Arbutus Biopharma Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.50
DETAILS
HIGH:
$8.50
LOW:
$8.50
MEDIAN:
$8.50
CONSENSUS:
$8.50
UPSIDE:
95.40%
Institutional Holders (13F)
| GURU | SHARES | VALUE | WEIGHT % | SHARES CHG | ACTION |
|---|---|---|---|---|---|
| Cooperman | 143,201 | $644,405 | 0.0% | -88,562 | DECREASED |
| Greenblatt | 17,321 | $77,945 | 0.0% | +17,321 | NEW |
Insider Trading
| DATE | INSIDER | TITLE | TYPE | SHARES | PRICE | VALUE |
|---|---|---|---|---|---|---|
| 2026-02-02 | Androski Lindsay | director, officer: President and CEO | A-Award | 28,000 | -- | -- |
| 2026-02-02 | Androski Lindsay | director, officer: President and CEO | A-Award | 71,700 | $4.39 | $315K |
| 2026-02-02 | Nguyen Tuan | officer: Chief Financial Officer | A-Award | 188,400 | $4.39 | $827K |
| 2026-02-02 | Nguyen Tuan | officer: Chief Financial Officer | A-Award | 73,500 | -- | -- |
| 2025-08-04 | Sawhney Roger | director | A-Award | 157,600 | $3.34 | $526K |
| 2025-08-04 | Sawhney Roger | director: | ? | -- | -- | -- |
| 2025-03-31 | Nguyen Tuan | officer: Chief Financial Officer | A-Award | 750,000 | $3.50 | $2.6M |
| 2025-03-28 | Nguyen Tuan | officer | ? | -- | -- | -- |
| 2025-03-18 | Hasija Anuj | director | A-Award | 157,600 | $3.20 | $504K |
| 2025-03-18 | Beardsley Robert A | director | A-Award | 157,600 | $3.20 | $504K |
| 2025-03-18 | Androski Lindsay | director, officer: President and CEO | A-Award | 310,422 | $3.20 | $993K |
| 2025-02-24 | Hasija Anuj | director: | ? | -- | -- | -- |
| 2025-02-24 | Bishop Joseph E | director: | ? | -- | -- | -- |
| 2025-02-24 | Beardsley Robert A | director: | ? | -- | -- | -- |
| 2025-02-24 | Androski Lindsay | director, officer: President and CEO | ? | -- | -- | -- |
| 2025-02-24 | Gline Matthew | director, 10 percent owner: | ? | -- | -- | -- |
| 2025-02-14 | Naftzger J. Christopher | officer: General Counsel and CCO | A-Award | 54,300 | -- | -- |
| 2025-02-14 | McElhaugh Michael J. | director, officer: Interim President & CEO | A-Award | 718,800 | $3.29 | $2.4M |
| 2025-02-14 | Sims Karen | officer: Chief Medical Officer | A-Award | 49,300 | -- | -- |
| 2025-02-14 | Naftzger J. Christopher | officer: General Counsel and CCO | A-Award | 220,300 | $3.29 | $725K |
| 2025-02-14 | Sims Karen | officer: Chief Medical Officer | A-Award | 200,300 | $3.29 | $659K |
| 2025-02-14 | McElhaugh Michael J. | director, officer: Interim President & CEO | A-Award | 177,000 | -- | -- |
| 2025-02-14 | HASTINGS DAVID C | officer: Chief Financial Officer | A-Award | 365,800 | $3.29 | $1.2M |
| 2025-02-14 | HASTINGS DAVID C | officer: Chief Financial Officer | A-Award | 90,100 | -- | -- |
| 2025-02-04 | HASTINGS DAVID C | officer: Chief Financial Officer | SELL | 22,183 | $3.28 | $73K |